Pediatric Vouchers Could Limit Adult Rare Disease Development, FDA Says
This article was originally published in The Pink Sheet Daily
Agency expands its critique of voucher incentive that it feels is a strain on agency resources.
You may also be interested in...
Stakeholders are sympathetic to FDA's concerns that voucher program requires diversion of precious resources, but some believe it provides substantial drug development incentive, particularly for small companies.
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Only about one-third of biosimilars received a first-cycle approval from US FDA after product quality discussions during the mid-assessment-cycle meeting, according to an interim report on the biosimilar application review program.